Program Activities

New NIDA PAs and RFAs

NIDA has reissued the International Research Collaboration on Drug Addiction Program Announcement soliciting collaborative research proposals on drug abuse and addiction that take advantage of unusual talent, resources, populations, or environmental conditions in other countries; speed scientific discovery; and meet NIDA research priorities. Applicants may propose investigations using the NIH Research Project (R01) mechanism. The new announcement, PA-06-050, uses standard receipt dates and expires January 3, 2009.

On November 9, 2005, NIDA issued a Program Announcement (PAS-06-066) entitled Design, Synthesis, and Preclinical Testing of Potential Treatment Agents for Drug Addiction. The purpose of this PA is to support research for the design, synthesis and pharmacological evaluation of new classes of compounds as potential treatment agents for cocaine, methamphetamine or cannabinoid addiction based on novel pharmacological interventions and molecular targets other than biogenic amine transporters.

On December 7, 2005, NIDA issued a Program Announcement (PA) entitled NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards (PA-06-036). This PA solicits Small Business Innovative Research (SBIR) grant applications from small business concers (SBCs) that propose the advance stage development of pharmacological treatment agents for drug and nicotine abuse and dependence.

On December 9, 2005, NIDA released a PA entitled Imaging - Science Track Award for Research Transition (I/START) (R03) (PAR-06-092). This PA is intended to facilitate the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs.

On November 8, 2005, NIDA issued an RFA entitled Developmental Centers for Translational Research on the Clinical Neurobiology of Drug Addiction (P20) (RFA-DA-06-006). This solicitation invites applications for the development of Translational Research Centers on the neurobiology of drug abuse and addiction. For purposes of this RFA, a Translational Research Center is defined as an entity with a primarily clinical/human neurobiology focus in which the preclinical research directly informs or provides a mechanistic foundation for the clinical research, and the preclinical science is informed and modified by the outcomes of the clinical research. Letter of Intent Receipt Date for this RFA: January 23, 2006; Application Receipt Date: February 23, 2006.

Two program announcements were released as a result of the work of the African American Initiative. One, which focuses on HIV/AIDS developed in collaboration with AIDS Program Office, is entitled Health Disparities in HIV/AIDS: Focus on African Americans (R01) (PA-06-069) (issued with NIMH). The other, which focuses on criminalization is entitled Drug Abuse as a Cause, Correlate, or Consequence of Criminal Justice Related Health Disparities among African Americans (R01) (PA-06-068).

In response to a call for Administrative Supplements for Research on the Intersection of Drug Use and Criminal Justice Consequences in the African American Population, NIDA awarded supplements to six grantees.

PAs and RFAs Issued With Other NIH Components/Agencies

On September 9, 2005, NIDA joined with NIMH in its issuance of PA-05-164, entitled Recent HIV Infection: New Prevention Challenges and Opportunities. This PA solicits innovative basic or applied HIV prevention science research to extend knowledge of the biological processes and behavioral risk contexts of acute and early HIV disease, and to identify and develop effective responses to specific prevention needs of highly infectious, newly HIV infected persons, who may account for a disproportionate share of secondary HIV transmissions.

On November 9, 2005, NIDA and NIMH jointly issued a PA entitled Non-Injection Drug Abuse and HIV/AIDS (R01) (PAS-06-054). The purpose of this PA is to encourage drug abuse research that elucidates the contribution of non-injection drug abuse to the acquisition and/or transmission and/or disease progression of HIV/AIDS. Specifically, it seeks to: 1) investigate how, where, why and among whom HIV/AIDS is spreading through non-injection drug use associated high-risk sexual behavior; 2) develop effective prevention and treatment interventions for non-injection drug users at risk for or infected with HIV; 3) and improve accessibility and utilization of evidence-based, integrated care for non-injection drug abuse, risky sexual behavior, and HIV/AIDS and other infectious diseases.

On December 15, 2005, NIDA and several other NIH Institutes released a PA entitled Parenting Capacities and Health Outcomes in Youths and Adolescents (R01) (PA-06-097). This PA solicits research applications aimed at increasing the parenting skills and capacities of parents and caregivers to improve the health outcomes of their young and adolescent children. This is important because childhood, and particularly adolescence, is a time for the development of health habits that can last a lifetime. Moreover, adolescence is a transitional period during which experimentation and high-risk health behaviors may be displayed. Parents and similarly situated caregivers of children 10-to-18 years of age are the targets of this initiative.

On December 15, 2005, NIDA and several other NIH Institutes released a PA entitled Parenting Capacities and Health Outcomes in Youths and Adolescents (R21) (PA-06-098). This PA solicits research applications aimed at increasing the parenting skills and capacities of parents and caregivers to improve the health outcomes of their young and adolescent children. This is important because childhood, and particularly adolescence, is a time for the development of health habits that can last a lifetime. Moreover, adolescence is a transitional period during which experimentation and high-risk health behaviors may be displayed. Parents and similarly situated caregivers of children 10-to-18 years of age are the targets of this initiative.

On December 27, 2005, NIDA and several other NIH Institutes issued a PA entitled Research on Pathways Linking Environments, Behaviors and HIV/AIDS (R01) (PAR-06-114). This PA calls for research studies on the relationships among social environments, individual behaviors and the incidence and prevalence of HIV/AIDS in populations.

On October 4, 2005, NIDA and numerous other NIH components issued a PA entitled Mentored Research Scientist Development Award (K01) (PA-06-001). The purpose of this PA is to provide support and "protected time" (three, four or five years) for an intensive, supervised career development experience in the biomedical, behavioral or clinical sciences leading to research independence.

On October 17, 2005, NIDA and numerous other NIH and DHHS components, issued a PA entitled Small Business Innovation Research Program Parent Announcement (SBIR [R43/R44]): Electronic Submission of Grant Applications through Grants.gov. (PA-06-006). The purpose of this Funding Opportunity Announcement (FOA) is to invite eligible US small business concerns (SBCs) to submit SBIR Phase I, Phase II, and Fast-Track grant applications through Grants..

On October 17, 2005, NIDA and numerous other NIH and DHHS components, issued a PA entitled Small Business Innovation Research Program Parent Announcement (STTR [R41/R42]): Electronic Submission of Grant Applications through Grants.gov. (PA-06-007). The purpose of this Funding Opportunity Announcement (FOA) is to invite eligible US small business concerns (SBCs) to submit SBIR Phase I, Phase II, and Fast-Track grant applications through Grants.gov.

On October 18, 2005, NIDA, in collaboration with numerous other NIH components, issued a PA entitled Small Business Innovation Research to Improve the Chemistry and Targeted Delivery of RNAi Molecules (STTR[R43/R4]) (PA-06-003). Through this PA, the participating NIH Institutes invite the small business community to apply cutting edge technology to develop new approaches and chemical modifications that will increase the long term stability, delivery and targeting of siRNAs in cells and tissues for laboratory and therapeutic applications.

On October 18, 2005, NIDA, in collaboration with numerous other NIH components, issued a PA entitled Small Business Innovation Research to Improve the Chemistry and Targeted Delivery of RNAi Molecules (SBIR[R41/R42]) (PA-06-004). Through this PA, the participating NIH Institutes invite the small business community to apply cutting edge technology to develop new approaches and chemical modifications that will increase the long term stability, delivery and targeting of siRNAs in cells and tissues for laboratory and therapeutic applications.

On October 18, 2005, NIDA, in collaboration with numerous other NIH components, issued a PA entitled Bioengineering Nanotechnology Initiative (STTR[R41/R42]) (PA-06-008). This Funding Opportunity Announcment (FOA), issued as an initiative of the trans-NIH Bioengineering Consortium (BECON) on behalf of the participating Institutes and Centers, invites Small Business Technology Transfer (STTR) grant applications for projects for developing and applying nanotechnology to biomedicine.

On October 18, 2005, NIDA, in collaboration with numerous other NIH components, issued a PA entitled Bioengineering Nanotechnology Initiative (SBIR[R43/R44]) (PA-06-009). This Funding Opportunity Announcment (FOA), issued as an initiative of the trans-NIH Bioengineering Consortium (BECON) on behalf of the participating Institutes and Centers, invites Small Business Innovation Research (SBIR) grant applications for projects for developing and applying nanotechnology to biomedicine.

On October 20, 2005, NIDA, in collaboration with numerous other NIH components, issued a PA entitled Manufacturing Processes of Medical, Dental, and Biological Technologies (STTR[R41/R42]) (PA-06-012). Through this PA, NIH is responding to Executive Order 13329 (requiring agencies, to the extent possible, to expand the focus of their SBIR and STTR programs to manufacturing-related research and development) by encouraging eligible US small business concers to submit STTR Phase I, Phase II and Fast-Track grant applications whose biomedical research is related to advanced processing, manufacturing processes, equipment and systems, and manufacturing workforce skills and protection.

On October 20, 2005, NIDA, in collaboration with numerous other NIH components, issued a PA entitled Manufacturing Processes of Medical, Dental, and Biological Technologies (SBIR[R43/R44]) (PA-06-013). Through this PA, NIH is responding to Executive Order 13329 (requiring agencies, to the extent possible, to expand the focus of their SBIR and STTR programs to manufacturing-related research and development) by encouraging eligible US small business concerns to submit SBIR Phase I, Phase II and Fast-Track grant applications whose biomedical research is related to advanced processing, manufacturing processes, equipment and systems, and manufacturing workforce skills and protection.

On October 17, 2005, NIDA and several other NIH Institutes jointly issued a PA entitled Development of PET and SPECT Ligands for Brain Imaging (SBIR[R43/R44]) (PA-06-017). This initiative is intended to stimulate the commercial development of noval radioligands for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging in human brain, and to incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies. The NIH Institues sponsoring this FOA are specifically interested in the development of radioligands for molecular targets (e.g., receptors, cell adhesion molecules, intracellular messengers, and disease-related proteins) that are of broad interest to the scientific community. These radiotracers will be used for neuroimaging as well as potential biological markers and surrogate endpoints for translational and clinical research, drug discovery and development, and clinical trials. Also appropriate for this FOA are applications proposing research and development of new technologies for radiotracer development.

On October 17, 2005, NIDA and several other NIH Institutes jointly issued a PA entitled Development of PET and SPECT Ligands for Brain Imaging (STTR[R41/R42]) (PA-06-018). This initiative is intended to stimulate the commercial development of noval radioligands for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging in human brain, and to incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies. The NIH Institues sponsoring this FOA are specifically interested in the development of radioligands for molecular targets (e.g., receptors, cell adhesion molecules, intracellular messengers, and disease-related proteins) that are of broad interest to the scientific community. These radiotracers will be used for neuroimaging as well as potential biological markers and surrogate endpoints for translational and clinical research, drug discovery and development, and clinical trials. Also appropriate for this FOA are applications proposing research and development of new technologies for radiotracer development.

On November 14, 2005, NIDA, along with a number of other NIH components, released a PA entitled Dissemination and Implementation Research in Health (R01) (PAR-06-0039). This PA encourages investigators to submit research grant applications that will identify, develop, and refine effective and efficient methods, structures and strategies that test models to disseminate and implement research-tested health behavior change interventions and evidence-based prevention, early detection, diagnostic, treatment, and quality of life improvement services into public health and clinical practice settings.

On November 14, 2005, NIDA, along with a number of other NIH components, released a PA entitled Dissemination and Implementation Research in Health (R03) (PAR-06-071). This PA encourages investigators to submit research grant applications that will identify, develop, and refine effective and efficient methods, structures and strategies that test models to disseminate and implement research-tested health behavior change interventions and evidence-based prevention, early detection, diagnostic, treatment, and quality of life improvement services into public health and clinical practice settings.

On November 14, 2005, NIDA, along with a number of other NIH components, released a PA entitled Dissemination and Implementation Research in Health (R21) (PAR-06-072). This PA encourages investigators to submit research grant applications that will identify, develop, and refine effective and efficient methods, structures and strategies that test models to disseminate and implement research-tested health behavior change interventions and evidence-based prevention, early detection, diagnostic, treatment, and quality of life improvement services into public health and clinical practice settings.

On October 26, 2005, NIDA, in conjunction with numerous other NIH components, issued a PA entitled NIH Support for Conferences and Scientific Meetings (R13/U13) (PA-06-041). This funding opportunity provides updated guidelines for NIH support of conferences and scientific meetings.

On October 26, 2005, NIDA, in conjunction with numerous other NIH components, issued a PA entitled Academic Research Enhancement Award (AREA) (R15) (PA-06-042). The purpose of the Academic Research Enhancement Award (AREA) is to stimulate research in educational institutions that provide baccalaureate or advances degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. These AREA grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH programs, to contribute to the Nation's biomedical and behavioral research effort.

On December 1, 2005, NIDA, in collaboration with a number of other NIH components, issued a PA entitled Research on Social Work Practice and Concepts in Health (R01) (PA-06-081). The ultimate goal of this PA is to encourage the development of empirical research on social work practice, concepts and theory as these relate to the NIH public health goal of improving health outcomes for persons with medical and behavioral disorders and conditions.

On December 1, 2005, NIDA, in collaboration with a number of other NIH components, issued a PA entitled Research on Social Work Practice and Concepts in Health (R03) (PA-06-082). The ultimate goal of this PA is to encourage the development of empirical research on social work practice, concepts and theory as these relate to the NIH public health goal of improving health outcomes for persons with medical and behavioral disorders and conditions.

On December 1, 2005, NIDA, in collaboration with a number of other NIH components, issued a PA entitled Research on Social Work Practice and Concepts in Health (R21) (PA-06-083). The ultimate goal of this PA is to encourage the development of empirical research on social work practice, concepts and theory as these relate to the NIH public health goal of improving health outcomes for persons with medical and behavioral disorders and conditions.

On December 2, 2005, NIDA, in collaboration with numerous other NIH components, issued a PA entitled Mentored Qualitative Research Development Award (K25) (PA-06-087). The purpose of this award is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease.

On December 19, 2005, NIDA, in collaboration with numerous other NIH components, issued a PA entitled Innovations in Biomedical Computational Science and Technology Initiative (SBIR [R43/R44]) (PAR-06-088). This announcement solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose innovative research in biomedical computational science and technology to promote the progress of biomedical research.

On December 19, 2005, NIDA, in collaboration with numerous other NIH components, issued a PA entitled Innovations in Biomedical Computational Science and Technology Initiative (STTR [R41/R42]) (PAR-06-089). This announcement solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose innovative research in biomedical computational science and technology to promote the progress of biomedical research.

On January 20, 2006, NIDA, in collaboration with numerous other NIH and DHHS components, issued a PA entitled PHS 2006-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) (PA-06-120). The purpose of this PA is to invite eligible US small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) Phase I, Phase II, Fast-Track, and Phase II Competing Renewal grant applications through Grants.gov.

On January 20, 2006, NIDA, in collaboration with numerous other NIH and DHHS components, issued a PA entitled PHS 2006-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent STTR [R41/R42]) (PA-06-121). The purpose of this PA is to invite eligible US small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) Phase I, Phase II, Fast-Track, and Phase II Competing Renewal grant applications through Grants.gov.

On November 10, 2005, NIDA, in collaboration with several other NIH Institutes and the Canadian Institutes of Health Research (CIHR), issued an RFA entitled Social Neuroscience (RFA-DA-06-004). The purpose of this RFA is to stimulate investigations of the cognitive/behavioral processes and neurobiological mechanisms of social behavior relevant to alcohol and drug abuse (NIDA/NIAAA) and decision making judgement over the life course (NIA). Clinical and preclinical research will be supported by this initiative. Letter of Intent Receipt Date for this RFA: January 23, 2006; Application Receipt Date: February 23, 2006.

On October 2, 2005, NIDA, in collaboration with the Canadian Institutes of Health Research (CIHR), issued an RFA entitled Epigenetics of Neurobiology and Addiction (RFA-DA-06-007). The goal of this RFA is to solicit applications that will link epigenetics changes to other biological changes (i.e., neuroplasticity) from gene expression to behavior (i.e., addiction). This RFA will also support the acquisition of preliminary data on epigenetic mechanisms related to addiction through a modified R03 funding mechanism. Letter of Intent Receipt Date for this RFA: December 23, 2005; Application Receipt Date: January 23, 2006.

On November 18, 2005, NIDA, in collaboration with the National Institute on Aging (NIA) and the National Institute of Dental and Craniofacial Research (NIDCR), issued an RFA entitled Prescription Opioid Use and Abuse in the Treatment of Pain (R01, R03, R21, R25) (RFA-DA-06-005). This RFA solicits new applications that examine risk and protective factors regarding the onset of opioid abuse and addiction in the context of pain, develop pain treatment protocols that are tailored to reduce the probability of these negative health consequences, and develop ways to ameliorate these problems when they occur. Letter of Intent Receipt Date for this RFA: January 23, 2006; Application Receipt Date: February 23, 2006.

On September 16, 2005, NIDA, in collaboration with a number of other NIH components, issued an RFA entitled Development and Improvement of Inbred ES Cell Lines for Use in Generation of Mouse Mutants (RFA-DA-06-009). The goal of this RFA is to improve the efficiency of germline transmission of C57BL/6 ES lines to an extent that permits the use of C57BL/6 ES cell for high throughput gene targeting and the efficient production of C57BL/6 mice carring a null mutation. Letter of Intent Receipt Date for this RFA: October 20, 2005; Application Receipt Date: November 22, 2005.

On November 15, 2005, NIDA, in collaboration with a number of other NIH components, issued an RFA entitled International Clinical, Operational and Health Services Research Training Award (ICOHRTA) [D43] (RFA-TW-06-002). This award will support advanced training in collaborative, multidisciplinary, international clinical, operational, health services and prevention science research on non-communicable disorders and diseases for health researchers from low- and middle-income countries. Letter of Intent Receipt Date for this RFA: December 26, 2005; Application Receipt Date: January 25, 2006.

On November 10, 2005, NIDA, in collaboration with numerous other NIH components, issued an RFA entitled course Development in the Neurobiology of Disease (R25) (RFA-DA-06-006). This RFA is an initiative of the NIH Blueprint for Neuroscience Research, a trans-NIH partnership to accelerate neuroscience research. Fifteen Institutes and Centers are participating in the Neuroscience Blueprint. This funding opportunity supports the development and initiation or the significant expansion of courses on the neurobiology of disease for graduate students receiving basic neuroscience training. It is expected that each course will span a breadth of diseases and disorders affecting the nervous system, emphasizing links and common themes across diseases/disorders, and addressing both the pathology af these diseases/disorders and their basic science underpinnings. Letter of Intent Receipt Date for this RFA: January 17, 2006; Application Receipt Date: February 16, 2006.

On September 29, 2005, NIDA, in collaboration with numerous other NIH components, issued an RFA entitled Neuroscience Blueprint Interdisciplinary Center Core Grants (RFA-NS-06-003). This RFA is an initiative of the NIH Blueprint for Neuroscience Research, a trans-NIH partnership to accelerate neuroscience research. Fifteen Institutes and Centers are participating in the Neuroscience Blueprint. Neuroscience Blueprint Interdisciplinary Center Core Grants will support centralized resources and facilities shared by neuroscience investigators. Each Center will be composed of one or more research cores, each of which will enrich the effectiveness of ongoing research and promote new research directions. Letter of Intent Receipt Date for this RFA: December 19, 2005; Application Receipt Date: January 19, 2006.

On November 9, 2005, NIDA, in collaboration with numerous other NIH components, issued an RFA entitled Training in Translational Research in Neurobiology of Disease (T32) (RFA-DA-06-008). This RFA is an initiative of the NIH Blueprint for Neuroscience Research, a trans-NIH partnership to accelerate neuroscience research. Fifteen Institutes and Centers are participating in the Neuroscience Blueprint. Through this RFA, NIH will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible institutions to support research trainees in translational research neurobiology of disease. Letter of Intent Receipt Date for this RFA: January 23 2006; Application Receipt Date: February 22, 2006.

On December 16, 2005, NIDA, in collaboration with numerous other NIH components, issued an RFA entitled Training in Computational Neuroscience: From Biology to Model and Back Again (T90) (RFA-DA-06-010). This RFA is an initiative of the NIH Blueprint for Neuroscience Research, a trans-NIH partnership to accelerate neuroscience research. Fifteen Institutes and Centers are participating in the Neuroscience Blueprint. This RFA will be administered by NIDA on behalf of the Neuroscience Blueprint. This funding opportunity will support integrated research education and research training programs that provide interdisciplinary training in basic neuroscience and the theoretical and technological approaches of computational neuroscience. Letter of Intent Receipt Date for this RFA: February 13, 2006; Application Receipt Date: March 13, 2006.

On December 23, 2005, NIDA, in collaboration with numerous other NIH components, issued an RFA entitled Training in Neuroimaging: Integrating First Principles and Applications (T90) (RFA-DA-06-011). This RFA is an initiative of the NIH Blueprint for Neuroscience Research, a trans-NIH partnership to accelerate neuroscience research. Fifteen Institutes and Centers are participating in the Neuroscience Blueprint. This funding opportunity will enable the development of novel, interdisciplinary training programs that integrate comprehensive training in basic neuroscience, the physical and biological bases of neuroimaging, the technologies and analytic methods on in vivo neuroimaging, and the application of these technologies to understanding questions in neuroscience across the lifespan. Letter of Intent Receipt Date for this RFA: February 13, 2006; Application Receipt Date: March 13, 2006.

On November 18, 2005, NIDA, in collaboration with numerous other NIH components, issued an RFA entitled Development of Recombinase-Expressing ("Driver") Mouse Lines for Studying the Nervous System (U01) (RFA-MH-06-007). This RFA is an initiative of the NIH Blueprint for Neuroscience Research, a trans-NIH partnership to accelerate neuroscience research. Fifteen Institutes and Centers are participating in the Neuroscience Blueprint. This funding opportunity supports the design, creation and characterization of recombinase-expressing C57BL/6 mouse lines to aid in studies of nervous system development and/or function. These so-called "driver lines" should specify expression in distinct cell types and/or other useful temporospatial expression patterns in the nervous system. Letter of Intent Receipt Date for this RFA: December 17, 2005; Application Receipt Date: January 19, 2006.

Other Program Activities

CTN Update

A total of 22 protocols and surveys have been initiated since 2001. A total of 11,314 patients were screened and 6,877 enrolled in studies as of December 14, 2005. Of these studies, 11 have completed enrollment and locked the data. Eleven protocols are currently active, and are summarized below:

Protocol CTN 0003 (Bup/Nx: Comparison of Two Taper Schedules) began enrollment June 30, 2003, data collection completed on November 3rd, 2005. Data lock is expected in March 2006.

Protocol CTN 0010 (Buprenorphine/Naloxone Facilitated Rehabilitation for Opioid Dependent Adolescents/Young Adults) began enrollment in July 2003. Enrollment is at 72% of the projected target.

Protocol CTN 0013 (Motivational Enhancement Therapy to Improve Treatment Utilization and Outcome In Pregnant Substance Abusers) began enrollment in November 2003 and has enrolled 90% of the projected target enrollment.

Protocol CTN 0014, Brief Strategic Family Therapy for Adolescent Drug Abusers (BSFT), has been implemented at 8 sites. The study has reached 44% enrollment.

Protocol CTN 0015 (Women's Treatment for Trauma and Substance Use Disorder: A Randomized Clinical Trial) began in March 2004. The study has reached its enrollment target, and follow-up continues.

Protocol CTN 0017 (HIV and HCV Intervention in Drug Treatment Settings). The study began enrollment in November 2004 and enrollment has reached 85% of the target goal. This study is enrolling at 8 community treatment sites across 5 Nodes.

CTN 0018 (Reducing HIV/STD Risk Behaviors: A Research Study for Men in Drug Abuse Treatment) began enrolling in April 2004 and has reached its target. The study is now in follow-up phase.

CTN 0019 (Reducing HIV/STD Risk Behaviors: A Research Study for Women in Drug Abuse Treatment) began enrollment in May 2004 and has reached its target. The study is now in follow-up phase.

CTN 0020 (Job Seekers Training for Substance Abusers). The protocol began enrollment in October 2004 and will have completed its enrollment goal as of December 31, 2005. This study is also being conducted in a Navajo American Indian site, the Na'nizhoozhi Center, Inc. in Gallup, New Mexico, the first CTN study to be conducted there.

Protocol CTN 0021(Motivational Enhancement Treatment to Improve Treatment Engagement and Outcome for Spanish-Speaking Individuals Seeking Treatment for Substance Abuse) began enrollment in November 2003 and reached its target goal in October 2005, and is in the follow up phase. This is the first Spanish-only protocol in the CTN.

Protocol CTN-0029: A Pilot Study of Osmotic-Release Methylphenidate (OROS MPH) in Initiating and Maintaining Abstinence in Smokers with Attention Deficit Hyperactivity Disorder (ADHD). Enrollment began at 3 sites in November 2005. The first patient was randomized on December 13, 2005. This study is being carried out at 6 CTPs across 5 Nodes.

Two protocols have recently locked their data sets and are at the analysis stage. Those include:

Protocol CTN 0004 (Motivational Enhancement Treatment to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse). Protocol CTN 0008 (Assessment of the National Drug Abuse Clinical Trials Network: A Baseline for Investigating Diffusion of Innovation) - The first group of publications is being reviewed internally by the Publications Committee prior to submission to peer reviewed journals.

Protocol CTN 0009 (Smoking Cessation Treatment with Transdermal Nicotine Replacement Therapy in Substance Abuse Rehabilitation Programs).

Protocol CTN 0012 (Characteristics of Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infections, and Sexually Transmitted Infections in Substance Abuse Treatment Programs) - The first publications from this study are being reviewed internally by the Publications Committee prior to submission to peer reviewed journals.

Four additional Protocols are currently being developed for the Network.

• Protocol CTN 0027: Starting Treatment with Agonist Replacement Therapies (START) is a randomized, open-label, multi-center study that was developed in collaboration with the Division of Pharmacotherapies & Medical Consequences of Drug Abuse (DPMCDA). Implementation is planned for April 2006.
• Protocol CTN 0028: Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS MPH) for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents with Substance Use Disorders (SUD). The protocol implementation is planned for February 2006.
• Protocol CTN 0030: Prescription Opioid Addiction Treatment Study (POATS) is a randomized 2-phases, open-label, multi-center study in outpatient treatment settings. Implementation is planned for Spring 2006.
• Protocol CTN 0031: Twelve Step Facilitation: Evaluation of an Intervention to Increase 12-Step Involvement and Improve Substance Abuse Treatment. This activity is at the concept development stage.

In addition to the primary CTN trials, there are 12 studies supported by independent grants or as supplements that use CTN studies as a platform.

NIDA's New and Competing Continuation Grants Awarded Since September 2005

Abdala, Nadia -- Yale University
Identifying HIV-Bridge-Population In STI Clinics, Russia

Andrews, Judy A. -- Oregon Research Institute
Substance Use & Girls: Stress, Hormones & Puberty

Astur, Robert S. -- Hartford Hospital
Cocaine-Induced Place Preference Using Virtual Reality

Avison, Malcolm J. -- Vanderbilt University
Neural Bases Of ADHD In Fetal Drug Or Alcohol Exposure

Beer, Jennifer S. -- University of California, Davis
Regulating Approach Impulses: Implications of Orbitofrontal Function For Addiction

Benowitz, Neal L. -- University of California, San Francisco
Pharmacogenetics of Nicotine Addiction and Treatment

Black, Maureen M. -- University of Maryland Baltimore Professional School
Prenatal Drug Exposure: Effects On Adolescent Brain

Booze, Rosemarie M. -- University of South Carolina at Columbia
HIV/Cocaine Neurotoxicity In Females

Brody, Arthur L. -- Brentwood Biomedical Research Institute
Nicotine Receptor Density & Dopamine System Function

Carroll, Frank I. -- Research Triangle Institute
Kappa Opioid Antagonist For Cocaine Addiction

Caton, Carol L. -- Columbia University Health Sciences
HIV Risk Among Homeless Mothers

Chang, Linda -- University of Hawaii at Manoa
Early Brain Development After Prenatal "Ice" Exposure: A Longitudinal MR Study

Colfax, Grant N. -- Public Health Foundation Enterprises
Acceptability Of Pharmacologic Treatment For Methamphetamine Dependence Among MSM

Crano, William D. -- Claremont Graduate University
Marijuana Use Patterns: Temporal Change In Predictors

De Bellis, Michael D. -- Duke University
Frontal Function In Adolescent Cannabis Use Disorders

De La Torre, Rafael -- Municipal Institute of Medical Research
Metabolism and Pharmacogenetics In MDMA-Induced Toxicity

Deisseroth, Karl A. -- Stanford University
Calcium Channels, Newborn Neurons, and CNS Circuit Dynamics

Dewey, Stephen L. -- Brookhaven Science Associates-Brookhaven Lab
Optimizing Intensity and Duration of GVG Pharmacotherapy

Dougherty, Donald M. -- Wake Forest University Health Sciences
Impulsivity and Information Processing In Adolescent Cannabis Abuse

Ducharme, Lori J. -- University of Georgia (UGA)
Comparison of Methadone Units Within and Outside The CTN

Dutta, Aloke K. -- Wayne State University
Dopamine Transporter Agents Against Cocaine Dependence

Dwoskin, Linda P. -- University of Kentucky
Nicotinic Receptor Regulation of Dopamine Transporter

Dwoskin, Linda P. -- University of Kentucky
Development of Novel Therapies for Methamphetamine Abuse

Farrelly, Matthew C. -- Research Triangle Institute
Macro-Social & Parent Influence On Adolescents' Drug Use

Fiez, Julie A. -- University of Pittsburgh at Pittsburgh
Neural Bases of Executive Control In Addiction

Fillmore, Mark T. -- University of Kentucky
Neurocognitive Consequences of Adolescent Drug Use

Fisher, Celia B. -- Fordham University
Participant Perspectives On Drug Use/HIV Research Ethics

Fisher, Philip A. -- Oregon Social Learning Center, Inc.
Kits: School Readiness In Foster Care Efficacy Trial

Fox, Howard S. -- Scripps Research Institute
Perilous Effects of Methamphetamine On SIV/AIDS

Fuller, Crystal -- Columbia University Health Sciences
Social Predictors For Transition Into Injection Drug Use

Gilman, Stephen -- Harvard University School of Public Health
Race, Socioeconomic Status, and Trajectories of Substance Use Disorders

Glass, Jennifer M. -- University of Michigan at Ann Arbor
Neurocognitive Risks & Consequences of Smoking

Gnegy, Margaret E. -- University of Michigan at Ann Arbor
Pharmacology of Dopamine Release By Amphetamine

Goodman, Richard H. -- Oregon Health & Science University
Gene Targets for Morphine and Other Drugs of Abuse

Goodwin, Renee D. -- Columbia University Health Sciences
Role of Depression and Anxiety In the Tobacco Epidemic

Green, Sarah A. -- Michigan Technological University
Identification of Short-Lived Radicals In Tobacco Smoke

Grigson, Patricia Sue -- Pennsylvania State University Hershey Medical Center
Drugs of Abuse and Learned Aversions: Solving A Paradox

Hart, Carl L. -- New York State Psychiatric Institute
Intranasal Methamphetamine: A Pharmacotherapy Model

Hauser, Kurt F. -- University of Kentucky
Mechanisms of Opiate Drug-HIV-Induced Neurodegeneration

Hook, Michelle A. -- Texas A&M University System
The Effects of Morphine On Sensory and Motor Functions After A Spinal Cord Injury

Huffman, John W. -- Clemson University
Synthesis of Cannabinoids, Analogues and Metabolites

Husbands, Stephen M. -- University of Bath
Discovery of New Treatments for Drug Abuse

Izenwasser, Sari -- University of Miami-Medical
Cocaine Behavior: Regulation By K-Opioids and Serotonin

Jacobsohn, Lela S. -- University of Pennsylvania
The Boomerang Effect of the Anti-Drug Media Campaign

Johnson, Bankole A. -- University of Virginia Charlottesville
Novel Pharmacotherapy For Dual Dependence

Johnson, Eric O. -- Research Triangle Institute
Pathway Among Co-Occurring Mental/Substance Use Disorder

Kabbaj, Mohamed -- Florida State University
Individual Differences In Anxiety In Females

Kalechstein, Ari D. -- University of California, Los Angeles
Methamphetamine Dependence: Treating Cognition Disorder

Karno, Mitchell P. -- University of California, Los Angeles
Factor Associated W/ Help-Seeking & Change In Drug Abuse

Kiehl, Kent A. -- Hartford Hospital
Neurocognitive Change Associated With Behavioral Treatment

King, Tamara -- University of Arizona
Effects of Sustained Opiates On Bone Metastasis and Pain

Kippin, Tod E. -- University of California, Santa Barbara
Sex Differences and Incubation of Cocaine Craving

Kopin, Alan S. -- New England Medical Center Hospitals
Molecular Analysis of Dopamine 2 Like Receptor Function

Kosobud, Ann E. -- Indiana University-Purdue University at Indianapolis
Role of Circadian Entrainment In Drug Intake and Abuse

Lai, Shenghan -- Johns Hopkins University
China Macs: An Exploratory Study

Lai, Shenghan -- Johns Hopkins University
Subclinical Atherosclerosis In HIV Plus Black Cocaine Users

Latimer, William -- Johns Hopkins University
Adapt IFCBT Into HIV Prevention Intervention

Lee, Buyean -- University of California, Los Angeles
Vervet Monkey Model For Methamphetamine-Induced Deficits In Response Inhibition

Lejuez, Carl W. -- University of Maryland, College Park
Behavioral Depression Treatment For Smoking Cessation

Lester, Henry A. -- California Institute of Technology
Nicotinic Ligands For Smoking Cessation

Liberty, Hilary J. -- National Development & Res Institutes
Understanding Self-Reports of Drug Use In Pregnant Women

London, Edythe D. -- University of California, Los Angeles
Neural Systems, Inhibitory Control, and Methamphetamine Dependence

Lucas, Gregory M. -- Johns Hopkins University
Directly Administered HIV Therapy In Methadone Clinics

Luongo, Peter F. -- Maryland State Department of Health and Mental Hygiene
Enhancing Adoption of Science-Based Practices

Lynch, Wendy J. -- University of Virginia, Charlottesville
Sex, Hormones and Cocaine Self-Administration

Martinez, Diana -- New York State Psychiatric Institute
Imaging ihe Neurobiology of A Behavioral Treatment

Martins, Silvia Saboia -- Johns Hopkins University
Predictors of Adolescent Ecstasy Use In The National Survey of Parents and Youth

Marvizon, Juan Carlos G. -- University of California, Los Angeles
Spinal Neurokinin and Opioid Release In Nociception

Matsueda, Ross L. -- University of Washington
Life Course Trajectories of Substance Use and Crime

McKay, Mary -- Mount Sinai School of Medicine of New York University
HIV/Drug Abuse Prevention For Homeless Youth & Families

McMahon, Thomas J. -- Yale University
Parent Intervention For Drug-Abusing Fathers

Newlin, David B. -- Research Triangle Institute
Weak Prefrontal Dc Stimulation and Tobacco Craving

Newton, Thomas F. -- University of California, Los Angeles
Laboratory Models of Cocaine Self-Administration

Nicosia, Nancy -- Rand Corporation
Impact of Amphetamine Abuse on Health and Crime

Patten, Christi A. -- Mayo Clinic College of Medicine, Rochester
Tobacco Cessation Treatment For Pregnant Alaska Natives

Picciotto, Marina R. -- Yale University
Nicotine Addiction In Mice Lacking The Neuronal nAChR

Potenza, Marc N. -- Yale University
fMRI of CBT and CM for Cocaine Dependence

Price, Rumi K. -- Washington University
Disentangling Substance Use and Psychiatric Disorder Comorbidity

Prisinzano, Thomas E. -- University of Iowa
Investigation of Neoclerodanes as Novel Opioid Ligands

Proudfit, Herbert K. -- University of Iowa
Dendritic Varicosities Regulate Neuronal Excitability

Ramsey, Susan E. -- Rhode Island Hospital, Providence, RI
Reducing HIV Risk Among Pregnant Women In Drug Treatment

Rasenick, Mark M. -- University of Illinois at Chicago
Structural Basis For Reciprocal Regulation of the Gtpases Tubulin and Gsalpha

Renshaw, Perry F. -- Mc Lean Hospital, Belmont, MA
Magnetic Resonance, EEG, and Behavior After Cocaine

Roberts, David C. -- Wake Forest University Health Sciences
Animal Models of Cocaine Addiction

Rush, Craig R. -- University of Kentucky
Preventing Cocaine Relapse: Developing Pharmacotherapies

Samaras, Dimitrios -- State University of New York, Stony Brook
CRCNS: Machine Learning for Analysis of fMRI

Schutzer, Steven E. -- University of Medicine/Dentistry of NJ-NJ Medical School
Complete Proteome Of Cerebrospinal Fluid

Shadel, William G. -- Rand Corporation
Adolescents' Responses To Anti-Smoking PSAs

Silverman, Kenneth -- Johns Hopkins University
Employment-Based Depot Naltrexone Clinical Trial

Sircar, Ratna -- Rutgers The State University of New Jersey, New Brunswick
Neurobehavioral Effects Of Adolescent GHB

Skosnik, Patrick D. -- Indiana University Bloomington
Sensory Processing Deficits In Cannabis Use

Smelson, David A. -- University of Medicine/Dentistry NJ-RWJ Medical School
Cue-Elicited Craving /Genetics In Relapse In Cocaine Use

Stein, Michael D. -- Rhode Island Hospital, Providence, RI
Insomnia and Drug Relapse Risk

Stenken, Julie -- Rensselaer Polytechnic Institute
Neuropeptide Affinity Enrichment Microdialysis Sampling

Strathdee, Steffanie A. -- University of California, San Diego
Epidemiology of HIV and BBVs Among IDUs In Tijuana

Sullivan, Maria A. -- New York State Psychiatric Institute
Predictors of Relapse To Prescription Opioid Abuse

Taxman, Faye S. -- Virginia Commonwealth University
Assessment and Referral Technologies In Juvenile Justice

Terzian, Arpi -- Johns Hopkins University
Physical Functioning In Women With HIV

Thomas, David L. -- Johns Hopkins University
HIV/HCV Coinfection Antiviral Therapy and Fibrosis

Turner, R Jay. -- Florida State University
Ethnic Contrasts In Mental Health and Substance Problems

Varga, Eva V. -- University of Arizona
Trafficking In Human CB1 Cannabinoid Receptor Signaling

Walkup, John T. -- Johns Hopkins University
In-Home Prevention Of SA Risks For Native Teen Families

Wallis, Jonathan D. -- University of California, Berkeley
The Neural Representation of Reward In Working Memory

Waters, Andrew J. -- University of Texas MD Anderson Cancer Center
Cognitive Processes In Smoking Cessation

Watson, Donnie W. -- Friends Research Institute, Inc.
Cognitive Behavioral Therapy For South Africa

Wechsberg, Wendee M. -- Research Triangle Institute
Woman-Focused HIV Prevention With Pregnant African-Americans In Treatment

Xie, Xiang-Qun -- University of Houston
A Public Cannabinoid Molecular Information Repository